Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

Claims 1-20 (Cancelled)

21. (Currently amended) A transgenic mouse whose genome comprises a heterozygous disruption in a serine protease gene comprising SEQ ID NO:1, wherein mating of such mice results in embryonic lethality of the embryos having a homozygous disruption in said gene~~where the disruption is heterozygous, and wherein, upon breeding with a second transgenic mouse whose genome comprises a disruption in the serine protease gene comprising SEQ ID NO:1, the transgenic mouse produces a transgenic mouse having a homozygous disruption in the serine protease gene comprising SEQ ID NO:1 and exhibiting a lethality during embryonic development~~.

22. (Currently amended) The transgenic mouse of claim 21, wherein the embryonic lethality occurs between about 12.5 and 14.5 days of embryonic growth.

23. (Currently amended) A method of producing ~~a~~ the transgenic mouse of claim 21~~whose genome comprises a disruption in a serine protease gene comprising SEQ ID NO:1~~, the method comprising:

    (a) providing a mouse embryonic stem cell comprising a disruption in the serine protease gene comprising SEQ ID NO:1;

    (b) introducing the mouse embryonic stem cell into a mouse blastocyst;

    (c) introducing the mouse blastocyst into a pseudopregnant mouse, wherein said pseudopregnant mouse gives birth to a chimeric mouse; and

    (d) breeding two chimeric mice to produce the transgenic mouse~~,~~ ~~wherein where the disruption is heterozygous, the transgenic mouse, upon breeding, produces a transgenic mouse whose genome comprises a homozygous disruption in the serine protease gene comprising SEQ ID NO:1 exhibiting a lethality during embryonic development~~.

Claims 24, 25 (Canceled).